An interventional study of Probiotic supplementation in Abdominal Pain (AP), Irritable Bowel Disease and Colonoscopy, sponsored by San Carlo di Nancy Hospital. Completed at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by San Carlo di Nancy Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Abdominal Pain with a site in Italy — none open to participants now, none under way, none of them phase 3. Abdominal Pain · Italy.
Among the 23 studies in Abdominal Pain with a site in Italy, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 23rd registered.
388 studies on the registry are indexed under Abdominal Pain; 58 are open to participants now.
Browse Abdominal Pain studies →None of the 23 studies in Abdominal Pain with a site in Italy is open now. The open studies under Abdominal Pain, anywhere →
Of the 33 Abdominal Pain studies recruiting now, 13 (39%) set no upper age limit and 17 (52%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 1998; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 70 across 291 interventional studies indexed under Abdominal Pain.
Median enrollment 65 across the 17 interventional studies, 159 across the 6 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
San Carlo di Nancy Hospital is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
San Carlo di Nancy Hospital has 1 study filed under Abdominal Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Abdominal Pain with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this open-label, pilot study, was to evaluate the impact of bowel preparation on IBS patients' gut microbiota, their recovery within thirty days, and whether the probiotic mixture administration contained in Lactichoc® altered their recovery from spontaneous resilience, while simultaneously monitoring the course of gastrointestinal symptoms. The primary objective of our study is to evaluate whether the administration of this probiotics modifies the recovery of the intestinal microbiota after colonoscopy preparation in patients with IBS in terms of speed (kinetics) and extent of recovery, compared to the spontaneous recovery observed in the control group. The secondary objective is to evaluate the effectiveness of probiotics in improving gastrointestinal symptoms and quality of life (GIQLI questionnaire) and stool consistency (Bristol scale), in patients with IBS undergoing colonoscopy, compared to an untreated control group.
For this study a total of 65 adult patients affected by IBS according to the Rome IV criteria were enrolled. We considered as drop out 4 patients because affected bycolon cancer (2 patients) and Inflammatory bowel disease (IBD) (2 patients). Data of 61 patients were analyzed: 30 were allocated to the Interventional group and 31 to the untreated control group. The cohort comprised 34 women and 25 men (sex not recorded for two patients), with a median age of 55 years (IQR 42-67), available for 49 patients. On the day of colonoscopy, after eligibility had been confirmed and the baseline GIQLI questionnaire collected, all patients underwent standard bowel preparation followed by colonoscopy with air insufflation - the same procedure in both arms, and therefore theperturbation common to the whole cohort. Only at the end of the examination were patientsrandomized, in a simple 1:1 ratio, to group A (probiotic group) or group B (control, without supplement).Patients in group A took two capsules per day of the product, equivalent to a total of 80 billionCFU/day, for ten consecutive days, starting from the day after of the endoscopic procedure. The mixture included eight strains: Bifidobacterium animalis subsp. lactis LA304 and LA804,Bifidobacterium bifidum LA803, Bifidobacterium breve LA805, Lactobacillus acidophilusLA201 and LA807, Lactobacillus gasseri LA806, and Lacticaseibacillus rhamnosus LA801.Group B received no supplementation and served as the control group. Throughout the study, patients in both groups were asked to maintain their usual dietary and physical-activity habit sand to avoid any additional probiotics, prebiotics, postbiotics or antibiotics unless clinically necessary. For each patient we collected a stool sample at three times: the first (T1) upon enrollment, beforeeven starting the preparation for the colonoscopy, so as to photograph the microbiota in its starting state. The second (T2) fourteen days after the colonoscopy and the third (T3) thirty days afterwards. For the purposes of this analysis, T1 represented the pre-colonoscopy baseline, whileT2 and T3 captured the early and later phases of microbiota recovery after bowel preparation, respectively. The laboratory of microbiology performed analysis of the stool samples for the gut microbiota. The results were then presented as relative abundances (%) of individual taxa, organized by health marker (gut barrier, inflammatory status, cardiometabolic marker, and gutbrain axis)along with phyla proportions, a bacterial diversity index, and quartile indices of dysbiosis andbutyrate producers, calculated relative to a healthy reference cohort. For each patient, the Firmicutes/Bacteroidetes ratio was also derived from the phyla proportion. Particular attention was paid to groups involved in short-chain fatty acid production, barrier function, and the gut-brain axis. Gastrointestinal symptoms and quality of life were assessed using the GIQLI (GastrointestinalQuality of Life Index) questionnaire, which provided the data collected and analysed in thepresent study. Stool form was additionally evaluated during the study visits using the Bristolscale as an internal clinical parameter; it was not recorded as a study variable and is therefore notincluded among the analysed outcomes.The GIQLI questionnaire was administered at the three study time points: T1, T2, and T3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Probiotic supplementation: 30 patients receive supplementation
Dietary Supplement: Probiotic supplementation
Control group: 31 patients don't receive supplementation
Patients received probiotics
Modification of gut microbiota
Evaluation of gut microbiota modification after the supplementation with probiotics (after colonoscopy)
Time frame: at baseline (T0), after 14 days from procedure (T1), and after 30 days (T2)
Gastrointestinal Symptoms in IBS
The secondary objective is to evaluate the effectiveness of probiotics in improving gastrointestinal symptoms and quality of life (GIQLI questionnaire) in patients with IBS undergoing colonoscopy, compared to an untreated control group at baseline (T0), after 14 days (T1), and after 30 days (T2). GIQLI questionnaire is a validate questionnaire composed by 33 questions , each with 5 answers.
Time frame: at baseline (T0), after 14 days from procedure (T1), and after 30 days (T2)
Plan to share: No
Ran from Jul 2025 to primary completion in Mar 2026, 8 months.
Of 86 non-industry interventional studies with no phase under Abdominal Pain, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 8 months is below that.
Counting every sponsor, half of 102 studies reached it within 12 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
San Carlo di Nancy Hospital